{"protocolSection":{"identificationModule":{"nctId":"NCT02538341","nctIdAliases":["NCT01967316","NCT02538757"],"orgStudyIdInfo":{"id":"VERVE-UM1"},"organization":{"fullName":"University of Alabama at Birmingham","class":"OTHER"},"briefTitle":"Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)","officialTitle":"Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)"},"statusModule":{"statusVerifiedDate":"2021-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-05","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-12","type":"ACTUAL"},"completionDateStruct":{"date":"2020-12","type":"ACTUAL"},"studyFirstSubmitDate":"2015-08-18","studyFirstSubmitQcDate":"2015-08-30","studyFirstPostDateStruct":{"date":"2015-09-02","type":"ESTIMATED"},"resultsFirstSubmitDate":"2020-10-28","resultsFirstSubmitQcDate":"2021-10-23","resultsFirstPostDateStruct":{"date":"2021-11-23","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-10-23","lastUpdatePostDateStruct":{"date":"2021-11-23","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Jeff Curtis, MD","investigatorTitle":"Principal Investigator","investigatorAffiliation":"University of Alabama at Birmingham"},"leadSponsor":{"name":"University of Alabama at Birmingham","class":"OTHER"},"collaborators":[{"name":"Oregon Health and Science University","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The VaricElla zosteR VaccinE (VERVE) trial evaluates the safety and effectiveness of the Herpes zoster (HZ) vaccine for shingles, Zostavax, in patients over 50 years old with arthritis and other diseases who are using anti-tumor necrosis factor (TNF) therapy and who have not previously received the vaccine.","detailedDescription":"Herpes zoster (HZ), also known as \"shingles\", is caused by reactivation and multiplication of the ubiquitous varicella zoster virus (VZV) that remains latent in everyone's sensory neurons following varicella, or \"chickenpox\". Among individuals who live to age 85, the lifetime risk for herpes zoster (HZ) is 50%, and more than one in five individuals affected by zoster develop post-herpetic neuralgia, resulting in chronic pain. Other serious complications include encephalitis, permanent vision loss, or more rarely, dissemination and death. Fortunately, a live attenuated vaccine is available and can reduce herpes zoster (HZ) risk by up to 70%. For patients with rheumatoid arthritis (RA), this vaccine has great potential to provide improved quality of life by reducing the incidence and complications associated with zoster. Due to the underlying disease and/or treatments (e.g. steroids) for rheumatoid arthritis (RA), the risk of herpes zoster (HZ) in rheumatoid arthritis patients is approximately double in the general population. This increased risk should make prevention of zoster and vaccination exceedingly important for rheumatoid arthritis patients. In fact, because of a higher overall absolute risk for herpes zoster (HZ) in rheumatoid arthritis, the vaccine yields a comparable or even greater absolute risk reduction to reduce the risk of shingles and post-herpetic neuralgia in a rheumatoid arthritis population as it does in the general population. However, the use of the herpes zoster (HZ) in rheumatoid arthritis, patients is very low (\\< 5%), and less frequently used than for the general population.\n\nNational guidelines from the Centers for Disease Control's (CDC) Advisory Committee on Immunization Practices (ACIP) recommend a single dose of the herpes zoster (HZ) vaccine for all individuals age 60 or older, with the vaccine more recently gaining Federal Drug Administration (FDA) -approval for administration to persons age 50 and older. While a large number of rheumatoid arthritis patients would otherwise be recommended to receive this vaccine on the basis of age, theoretical safety concerns related to vaccination likely explain the very low vaccination rates observed. Currently, the Federal Drug Administration (FDA), the Advisory Committee on Immunization Practices (ACIP), and the American College of Rheumatology (ACR) consider the live zoster vaccine contraindicated in patients receiving immunosuppressive medications, such as biologic therapies. Such contraindication stems from the theoretical safety concern that these individuals could develop a varicella-like infection from the vaccine virus strain. However, investigators hypothesize that this vaccine can safely be given in this setting, as no published data is available to suggest that these safety concerns are warranted. A growing body of observational data suggests that vaccinating rheumatoid arthritis patients receiving biologic therapies with this vaccine may in fact be safe. Moreover, and similarly with little or no evidence, the Advisory Committee on Immunization Practices (ACIP) considers the vaccine safe and acceptable for patients using methotrexate at doses commonly used to treat rheumatoid arthritis (e.g. \\<= 25mg/week) and for patients using glucocorticoids at prednisone-equivalent doses of ≤ 20 mg/day.\n\nIn light of 1) a substantial elevated herpes zoster (HZ) risk among rheumatoid arthritis patients; 2) national data showing most rheumatoid arthritis patients are not vaccinated for herpes zoster (HZ) ; and 3) the high effectiveness of this vaccine in the general population, the investigators propose to conduct the Varicella zostER VaccinE (VERVE) trial, a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and long-term effectiveness of the live herpes zoster (HZ) vaccine. This study will recruit 1,000 individuals age 50 years or older currently receiving anti-tumor necrosis factor (TNF) therapy for rheumatoid arthritis or other diseases. Within a relevant 6-week safety window, the investigators will collect serious adverse events (satisfying a regulatory definition of a Serious Adverse Event) including non-serious events of vaccine-strain varicella-like infection or herpes zoster (HZ). Beyond the key public health importance of the clinical question addressed, clinical trial methodological innovations anticipated for this unique large pragmatic trial. Additionally, the investigators will study vaccine tolerability and long-term effectiveness through a linkage to health plan data to allow for cost-effective follow-up while minimizing participant and study-site burden. Results from this study will facilitate the parent trial and change rheumatoid arthritis management by demonstrating the clinical safety and immunogenicity of the live zoster vaccine among current anti-tumor necrosis factor (TNF) users. Rheumatologists and other providers will be able to improve the care, outcomes, and quality of life for patients using anti-tumor necrosis factor (TNF) therapy, substantially decreasing the morbidity of herpes zoster and its complications over a lifetime."},"conditionsModule":{"conditions":["Rheumatoid Arthritis","Inflammatory Arthritis","Arthritis","Psoriatic Arthritis","Psoriasis","Ankylosing Spondylitis","Enteropathic Arthritis","Crohn's Disease"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":617,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Zostavax (Zoster Vaccine Live)","type":"ACTIVE_COMPARATOR","description":"Zostavax (zoster vaccine live) is used to prevent herpes zoster (HZ) virus (shingles) in people age 50 and older. Patients randomized to this arm will receive active herpes zoster (HZ) vaccine. It is administered as a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.","interventionNames":["Biological: Herpes Zoster (HZ) Vaccine"]},{"label":"Placebo Normal Saline","type":"PLACEBO_COMPARATOR","description":"Saline injection: patients randomized to this arm will receive a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Herpes Zoster (HZ) Vaccine","armGroupLabels":["Zostavax (Zoster Vaccine Live)"],"otherNames":["Zostavax"]},{"type":"DRUG","name":"Placebo","armGroupLabels":["Placebo Normal Saline"],"otherNames":["Normal Saline"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"GMFR (Geometric Mean Fold Rise ) in Varicella Zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Immunoglobulin G (IgG) Levels From Baseline at 6 Weeks","description":"Study protocol defined measure for immunogenicity samples.","timeFrame":"6 weeks post vaccination"},{"measure":"GMFR (Geometric Mean Fold Rise ) in Varicella Zoster Virus (VZV) Enzyme-linked Immune Absorbent Spot (ELISpot) Interferon Gamma (IFNg) Levels From Baseline at 6 Weeks","description":"Study protocol defined measure for immunogenicity samples.","timeFrame":"6 weeks post vaccination"}],"secondaryOutcomes":[{"measure":"GMFR (Geometric Mean Fold Rise ) in Varicella Zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Immunoglobulin G (IgG) Levels From Baseline at 1 Year","description":"Study defined measure from labs. GMFR (Geometric Mean Fold Rise ) in varicella zoster virus (VZV) glycoprotein enzyme-linked immunosorbent assay (gpELISA) immunoglobulin G (IgG) levels","timeFrame":"Baseline to 1 year"},{"measure":"GMFR (Geometric Mean Fold Rise ) in Varicella Zoster Virus (VZV) Enzyme-linked Immune Absorbent Spot (ELISpot) Interferon Gamma (IFNg) Levels From Baseline at 1 Year","description":"Study defined measures from labs. GMFR (Geometric Mean Fold Rise ) in Varicella Zoster Virus (VZV) enzyme-linked immune absorbent spot (ELISpot) interferon gamma (IFNg)","timeFrame":"Baseline to 1 year"},{"measure":"Number of Samples With Confirmed Varicella","description":"Evaluated all serious adverse events (SAEs) AND non-serious varicella zoster virus (VZV) events","timeFrame":"\"Placebo Normal Saline Arm/Group was assessed up to 6 months and the \"Zoster Vaccine Live (Zostavax)\" Arm/Group was assessed up to 1 year"},{"measure":"Vaccine Tolerability Within 42 Days Following Vaccination.","description":"Patient self report data in the form of a diary to include injection site reactions; symptoms of swelling, redness or tenderness. Diary was completed from study injection administration up to 6 week visit","timeFrame":"42 days post vaccination"},{"measure":"Evaluate Rheumatoid Arthritis Disease Activity Using the Clinical Disease Activity Index (CDAI)","description":"Rheumatoid arthritis disease activity will be measured using the clinical disease activity index (CDAI). Clinical disease activity index (CDAI) is a measure of rheumatoid arthritis disease activity and is scored on a scale ranging from 0-76, with lower numbers indicated better control of disease. Values \\<=10 are consistent with low disease activity or remission.","timeFrame":"42 days post vaccination"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must be 50 years of age or older\n* Must be currently treated with an anti-tumor necrosis factor (TNF) therapy\\*\\* at the time of study drug administration, allowing for small deviations in dosing frequency and logistic feasibility (e.g. study visits to occur on a week day). Date of previous dose of medication is required. Specifically, meets one of the following: Etanercept dose within 9 days (1 week + 2 days), Adalimumab dose within 16 days (2 weeks + 2 days), Certolizumab Subcutaneous (SC) dose within 16 to 32 days depending on frequency schedule (2 weeks + 2 days, or 4 weeks and 4 days), Golimumab Subcutaneous (SC) dose within 32 days (4 weeks + 4 days), Golimumab Intravenous (IV) dose within 64 days (9 weeks + 1 day), Infliximab IV dose within last 64 days (9 weeks + 1 day)\n\n  \\*\\*any form of biosimilar for the above listed anti-tumor necrosis factor (TNF) medications is acceptable\n* Diagnosis of rheumatoid arthritis or another inflammatory arthritis (Phase 1A); or other inflammatory condition (e.g. psoriasis) requiring use of anti-tumor necrosis factor (TNF) therapy (Phase 1B and II)\n* Phase I subjects must test positive for varicella-zoster virus (VZV) antibody immunoglobulin G (IgG)\n* Subjects should have a self-reported history of prior varicella infection (i.e. chicken pox) or long-term residence (\\>30 years) in the continental United States.\n* Phase IA subjects must not have received any oral or systemic glucocorticoids within 30 days prior to vaccination. Intra-articular glucocorticoid injections and inhaled glucocorticoids within the previous 30 days are acceptable.\n* Subjects should be on stable doses of all biologic and non-biologic Disease-modifying antirheumatic drugs (DMARDs) for a minimum of 30 days prior to vaccination.\n* Eligible women must be post-menopausal (\\> 1 year since last menstrual period) or have a surgical history of bilateral oophorectomy or hysterectomy.\n* Subjects should be ambulatory, community dwelling and capable of giving informed consent.\n\nExclusion Criteria:\n\n* Documented varicella-zoster virus (VZV) antibody immunoglobulin G (IgG) negative result\n* Prior use of the zoster vaccine (Zostavax®, Merck)\n* Glucocorticoids at a prednisone-equivalent daily dose \\> 10mg/day (for Phase 1B and Phase II participants; all systemic glucocorticoid use is prohibited for Phase 1A patients)\n* Any known contraindication to Zostavax® vaccine, including allergy or sensitivity to gelatin or any other vaccine component\n* Known human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)\n* Currently receiving radiation or chemotherapy for any type of malignancy\n* Any current use (within the last 30 days) of acyclovir, valacyclovir, famciclovir, or foscarnet\n* Receipt of any other immunizations within one month before study vaccination (2 weeks in the case of inactivated influenza vaccines or other non-replicating immunization products \\[e.g., diphtheria-tetanus (dT), pneumococcal vaccine, hepatitis A vaccine, hepatitis B vaccine\\]), or scheduled within 6 weeks after recruitment.\n* Active infection or inter-current illness (e.g., urinary tract infection, influenza)\n* Participated in an investigational study within 1 month prior to study entry\n* Active drug or alcohol use, dependence, or any other reason that, in the opinion of the site investigator, would interfere with the study\n* Significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 3 years)\n* Any other reason that, in the opinion of the site investigator, would interfere with required study related evaluations (e.g. uncontrolled comorbidity, life expectancy \\< 1 year)\n* Patients who have household contact with varicella-susceptible pregnant women or severely immunosuppressed individuals without history of primary varicella.","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Jeffrey R Curtis, MD, MS, MPH","affiliation":"University of Alabama at Birmingham","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Rheumatology Associates, PC","city":"Birmingham","state":"Alabama","zip":"35205","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"Total Skin and Beauty Dermatology Center, PC","city":"Birmingham","state":"Alabama","zip":"35205","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"University of Alabama at Birmingham","city":"Birmingham","state":"Alabama","zip":"35294","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"Rheumatology Associates of North Alabama, PC","city":"Huntsville","state":"Alabama","zip":"35801","country":"United States","geoPoint":{"lat":34.7304,"lon":-86.58594}},{"facility":"Clinical and Translational Research Center of Alabama, PC","city":"Tuscaloosa","state":"Alabama","zip":"35406","country":"United States","geoPoint":{"lat":33.20984,"lon":-87.56917}},{"facility":"SunValley Arthritis Center, Ltd","city":"Peoria","state":"Arizona","zip":"85381","country":"United States","geoPoint":{"lat":33.5806,"lon":-112.23738}},{"facility":"Arthritis Association of Southern California","city":"Los Angeles","state":"California","zip":"90015","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"The Regents of the University of California Los Angeles","city":"Los Angeles","state":"California","zip":"90095","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Rheumatology Consultants of Delaware dba Delaware Arthritis","city":"Lewes","state":"Delaware","zip":"19958","country":"United States","geoPoint":{"lat":38.77456,"lon":-75.13935}},{"facility":"Center for Arthritis and Rheumatic Diseases","city":"Miami","state":"Florida","zip":"33157","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Coral Research Clinic Corp","city":"Miami","state":"Florida","zip":"33175","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Arthritis Research of Florida, Inc","city":"Palm Harbor","state":"Florida","zip":"34684","country":"United States","geoPoint":{"lat":28.07807,"lon":-82.76371}},{"facility":"Sarasota Arthritis Research Center","city":"Sarasota","state":"Florida","zip":"34239","country":"United States","geoPoint":{"lat":27.33643,"lon":-82.53065}},{"facility":"West Broward Rheumatology Associates, Inc","city":"Tamarac","state":"Florida","zip":"33321","country":"United States","geoPoint":{"lat":26.21286,"lon":-80.24977}},{"facility":"North Georgia Rheumatology Group","city":"Lawrenceville","state":"Georgia","zip":"30046","country":"United States","geoPoint":{"lat":33.95621,"lon":-83.98796}},{"facility":"Arthritis Research Center Foundation, NDB","city":"Wichita","state":"Kansas","zip":"67214","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"Ochsner Clinic Baton Rouge","city":"Baton Rouge","state":"Louisiana","zip":"70809","country":"United States","geoPoint":{"lat":30.44332,"lon":-91.18747}},{"facility":"Ochsner Clinic Foundation, New Orleans","city":"New Orleans","state":"Louisiana","zip":"70121","country":"United States","geoPoint":{"lat":29.95465,"lon":-90.07507}},{"facility":"Rheumatology & Osteoporosis Specialists","city":"Shreveport","state":"Louisiana","zip":"71101","country":"United States","geoPoint":{"lat":32.52515,"lon":-93.75018}},{"facility":"Boston Medical Center","city":"Boston","state":"Massachusetts","zip":"02118","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Pine Hollow Partners","city":"East Lansing","state":"Michigan","zip":"48823","country":"United States","geoPoint":{"lat":42.73698,"lon":-84.48387}},{"facility":"St. Paul Rheumatology","city":"Eagan","state":"Minnesota","zip":"55121","country":"United States","geoPoint":{"lat":44.80413,"lon":-93.16689}},{"facility":"University of Nebraska Medical Center","city":"Omaha","state":"Nebraska","zip":"68106","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"The Center for Rheumatology, LLP","city":"Albany","state":"New York","zip":"12293","country":"United States","geoPoint":{"lat":42.65258,"lon":-73.75623}},{"facility":"Mary Imogene Bassett Hospital, Bassett Research Institute","city":"Cooperstown","state":"New York","zip":"13326","country":"United States","geoPoint":{"lat":42.70048,"lon":-74.92426}},{"facility":"The Ohio State University","city":"Columbus","state":"Ohio","zip":"43203","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Oregon Health & Science University","city":"Portland","state":"Oregon","zip":"97239","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Altoona Center for Clinical Research","city":"Duncansville","state":"Pennsylvania","zip":"16635","country":"United States","geoPoint":{"lat":40.42341,"lon":-78.4339}},{"facility":"Carolina Health Specialists","city":"Myrtle Beach","state":"South Carolina","zip":"29572","country":"United States","geoPoint":{"lat":33.68906,"lon":-78.88669}},{"facility":"Arthritis Associates, PLLC","city":"Hixson","state":"Tennessee","zip":"37343","country":"United States","geoPoint":{"lat":35.14063,"lon":-85.23273}},{"facility":"West Tennessee Research Institute","city":"Jackson","state":"Tennessee","zip":"38305","country":"United States","geoPoint":{"lat":35.61452,"lon":-88.81395}},{"facility":"Southwest Rheumatology Research, LLC","city":"Mesquite","state":"Texas","zip":"75150","country":"United States","geoPoint":{"lat":32.7668,"lon":-96.59916}},{"facility":"University of Texas Health Science Center at San Antonio","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"West Virginia Research Institute, PLLC","city":"South Charleston","state":"West Virginia","zip":"25309","country":"United States","geoPoint":{"lat":38.36843,"lon":-81.69957}}]},"referencesModule":{"references":[{"pmid":"34570596","type":"DERIVED","citation":"Curtis JR, Cofield SS, Bridges SL Jr, Bassler J, Deodhar A, Ford TL, Huffstutter J, Jankeel A, Kivitz A, Kamal S, Lindsey S, Messaoudi I, Mendoza N, Michaud K, Mikuls TR, Ridley D, Shergy W, Siegel SAR, Winthrop KL. The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy : A Randomized Controlled Trial. Ann Intern Med. 2021 Nov;174(11):1510-1518. doi: 10.7326/M20-6928. Epub 2021 Sep 28."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","infoTypes":["STUDY_PROTOCOL"]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Zoster Vaccine Live (Zostavax)","description":"Zostavax (zoster vaccine live) is used to prevent herpes zoster virus (shingles) in people age 50 and older. Patients randomized to this arm will receive active Herpes Zoster Vaccine. It is administered as a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.\n\nHerpes Zoster Vaccine"},{"id":"FG001","title":"Placebo Normal Saline","description":"Saline injection: patients randomized to this arm will receive a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.\n\nPlacebo"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"310"},{"groupId":"FG001","numSubjects":"307"}]},{"type":"Week 6 (Primary Outcome)","achievements":[{"groupId":"FG000","numSubjects":"303"},{"groupId":"FG001","numSubjects":"299"}]},{"type":"Month 6 (Safety Outcome)","comment":"All participants were followed in a blinded manner until Month 6 when clinical sites and participants were unblinded. Participants randomized to placebo completed the study at Month 6.","achievements":[{"groupId":"FG000","numSubjects":"276"},{"groupId":"FG001","numSubjects":"260"}]},{"type":"1 Year Visit","comment":"As an exploratory outcome to assess the immunologic persistence of live herpes zoster vaccine among participants randomized to the vaccine, only those participants were invited to provide a Year 1 blood sample for the same lab assessments.","achievements":[{"groupId":"FG000","numSubjects":"254"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"254"},{"groupId":"FG001","numSubjects":"260"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"56"},{"groupId":"FG001","numSubjects":"47"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"51"},{"groupId":"FG001","numSubjects":"46"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Zoster Vaccine Live (Zostavax)","description":"Zostavax (zoster vaccine live) is used to prevent herpes zoster virus (shingles) in people age 50 and older. Patients randomized to this arm will receive active Herpes Zoster Vaccine. It is administered as a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.\n\nHerpes Zoster Vaccine"},{"id":"BG001","title":"Placebo Normal Saline","description":"Saline injection: patients randomized to this arm will receive a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.\n\nPlacebo"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"310"},{"groupId":"BG001","value":"307"},{"groupId":"BG002","value":"617"}]}],"measures":[{"title":"Age, Customized","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"title":"Age","categories":[{"measurements":[{"groupId":"BG000","value":"62.7","spread":"7.6"},{"groupId":"BG001","value":"63.1","spread":"7.4"},{"groupId":"BG002","value":"62.9","spread":"7.5"}]}]}]},{"title":"Age, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"Age","categories":[{"title":"50-59","measurements":[{"groupId":"BG000","value":"126"},{"groupId":"BG001","value":"102"},{"groupId":"BG002","value":"228"}]},{"title":"60-69","measurements":[{"groupId":"BG000","value":"125"},{"groupId":"BG001","value":"142"},{"groupId":"BG002","value":"267"}]},{"title":"70-79","measurements":[{"groupId":"BG000","value":"50"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"105"}]},{"title":"80-89","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"16"}]},{"title":"90-99","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"207"},{"groupId":"BG001","value":"201"},{"groupId":"BG002","value":"408"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"103"},{"groupId":"BG001","value":"106"},{"groupId":"BG002","value":"209"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"38"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"202"},{"groupId":"BG001","value":"197"},{"groupId":"BG002","value":"399"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"81"},{"groupId":"BG001","value":"91"},{"groupId":"BG002","value":"172"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"Ethnicity","categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"26"}]},{"title":"Not Hispanic","measurements":[{"groupId":"BG000","value":"208"},{"groupId":"BG001","value":"194"},{"groupId":"BG002","value":"402"}]},{"title":"Other Ethnicity","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"14"}]},{"title":"Unknown/ Not reported","measurements":[{"groupId":"BG000","value":"81"},{"groupId":"BG001","value":"94"},{"groupId":"BG002","value":"175"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"310"},{"groupId":"BG001","value":"307"},{"groupId":"BG002","value":"617"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"GMFR (Geometric Mean Fold Rise ) in Varicella Zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Immunoglobulin G (IgG) Levels From Baseline at 6 Weeks","description":"Study protocol defined measure for immunogenicity samples.","populationDescription":"Zoster vaccine live arm 7 did not complete Week 6; 5 lost to follow-up, 2 withdrew consent. Placebo arm 8 did not complete Week 6; 5 lost to follow-up, 3 withdrew consent. Zoster vaccine live arm 300 immunogenicity samples collected, 294 useable immunoglobulin G (IgG) samples, 287 usable immunoglobulin G (IgG) sample pairs. For the placebo arm 298 immunogenicity samples collected, 289 useable immunoglobulin G (IgG) samples, 259 usable immunoglobulin G (IgG) sample pairs.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"GMFR (Geometric Mean Fold Rise )","timeFrame":"6 weeks post vaccination","typeUnitsAnalyzed":"IgG samples pairs","denomUnitsSelected":"IgG samples pairs","groups":[{"id":"OG000","title":"Zoster Vaccine Live (Zostavax)","description":"Zostavax (zoster vaccine live) is used to prevent herpes zoster virus (shingles) in people age 50 and older. Patients randomized to this arm will receive active Herpes Zoster Vaccine. It is administered as a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.\n\nHerpes Zoster Vaccine"},{"id":"OG001","title":"Placebo Normal Saline","description":"Saline injection: patients randomized to this arm will receive a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.\n\nPlacebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"303"},{"groupId":"OG001","value":"299"}]},{"units":"IgG samples pairs","counts":[{"groupId":"OG000","value":"287"},{"groupId":"OG001","value":"289"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.33","lowerLimit":"1.17","upperLimit":"1.51"},{"groupId":"OG001","value":"1.02","lowerLimit":"0.91","upperLimit":"1.14"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Study protocol defined measure for immunogenicity samples. Participants must have at least 1 post vaccine immunogenicity measure to determine the GMFR (a priori analysis)","nonInferiorityType":"OTHER","pValue":"0.0023","pValueComment":"p values, from a generalized linear model on the rank order of the week 6 - baseline change using normal distribution and reciprocal link.","statisticalMethod":"a generalized linear model","statisticalComment":"p value,from a generalized linear model on the rank order of the week 6 - baseline change using normal distribution and reciprocal link."}]},{"type":"PRIMARY","title":"GMFR (Geometric Mean Fold Rise ) in Varicella Zoster Virus (VZV) Enzyme-linked Immune Absorbent Spot (ELISpot) Interferon Gamma (IFNg) Levels From Baseline at 6 Weeks","description":"Study protocol defined measure for immunogenicity samples.","populationDescription":"Zoster vaccine live arm 7 did not complete Week 6; 5 lost to follow-up, 2 withdrew consent. Placebo arm 8 did not complete Week 6; 5 lost to follow-up, 3 withdrew consent. For the zoster vaccine live arm 300 immunogenicity samples collected, 290 useable interferon gamma (IFNg) samples, 259 usable interferon gamma (IFNg) sample pairs. For the placebo arm 298 immunogenicity samples collected, 289 useable interferon gamma (IFNg) samples, 275 usable interferon gamma (IFNg)sample pairs.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"GMFR (Geometric Mean Fold Rise )","timeFrame":"6 weeks post vaccination","typeUnitsAnalyzed":"lab samples pairs","denomUnitsSelected":"lab samples pairs","groups":[{"id":"OG000","title":"Zoster Vaccine Live (Zostavax)","description":"Zostavax (zoster vaccine live) is used to prevent herpes zoster virus (shingles) in people age 50 and older. Patients randomized to this arm will receive active Herpes Zoster Vaccine. It is administered as a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.\n\nHerpes Zoster Vaccine"},{"id":"OG001","title":"Placebo Normal Saline","description":"Saline injection: patients randomized to this arm will receive a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.\n\nPlacebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"303"},{"groupId":"OG001","value":"299"}]},{"units":"lab samples pairs","counts":[{"groupId":"OG000","value":"259"},{"groupId":"OG001","value":"275"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.39","lowerLimit":"1.07","upperLimit":"1.82"},{"groupId":"OG001","value":"1.15","lowerLimit":"0.88","upperLimit":"1.50"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Study protocol defined measure for immunogenicity samples. Participants must have at least 1 post vaccine immunogenicity measure to determine the GMFR (a priori analysis)","nonInferiorityType":"OTHER","pValue":"0.31","pValueComment":"p values, from a generalized linear model on the rank order of the week 6 - baseline change using normal distribution and reciprocal link.","statisticalMethod":"a generalized linear model","statisticalComment":"p values, from a generalized linear model on the rank order of the week 6 - baseline change using normal distribution and reciprocal link."}]},{"type":"SECONDARY","title":"GMFR (Geometric Mean Fold Rise ) in Varicella Zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Immunoglobulin G (IgG) Levels From Baseline at 1 Year","description":"Study defined measure from labs. GMFR (Geometric Mean Fold Rise ) in varicella zoster virus (VZV) glycoprotein enzyme-linked immunosorbent assay (gpELISA) immunoglobulin G (IgG) levels","populationDescription":"Zoster vaccine live arm 56 did not complete Year 1; 51 lost to follow-up, 3 withdrew consent, 2 deaths prior to month 6. Vaccine arm only. Placebo arm not applicable for this exploratory outcome. For the zoster vaccine live arm 131 immunogenicity samples collected, 122 useable immunoglobulin G (IgG) samples, 114 usable immunoglobulin G (IgG) sample pairs.","reportingStatus":"POSTED","paramType":"COUNT_OF_UNITS","unitOfMeasure":"lab samples","timeFrame":"Baseline to 1 year","typeUnitsAnalyzed":"lab samples","denomUnitsSelected":"lab samples","groups":[{"id":"OG000","title":"Zoster Vaccine Live (Zostavax)","description":"Zostavax (zoster vaccine live) is used to prevent herpes zoster virus (shingles) in people age 50 and older. Patients randomized to this arm will receive active Herpes Zoster Vaccine. It is administered as a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.\n\nHerpes Zoster Vaccine"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"254"}]},{"units":"lab samples","counts":[{"groupId":"OG000","value":"114"}]}],"classes":[{"title":"≤ Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"41"}]}]},{"title":"Within 20%","categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]},{"title":"> 20%","categories":[{"measurements":[{"groupId":"OG000","value":"67"}]}]}]},{"type":"SECONDARY","title":"GMFR (Geometric Mean Fold Rise ) in Varicella Zoster Virus (VZV) Enzyme-linked Immune Absorbent Spot (ELISpot) Interferon Gamma (IFNg) Levels From Baseline at 1 Year","description":"Study defined measures from labs. GMFR (Geometric Mean Fold Rise ) in Varicella Zoster Virus (VZV) enzyme-linked immune absorbent spot (ELISpot) interferon gamma (IFNg)","populationDescription":"Zoster vaccine live arm 56 did not complete Year 1; 51 lost to follow-up, 3 withdrew consent, 2 deaths prior to month 6. Vaccine arm only. Placebo arm not applicable. For the zoster vaccine live arm 131 immunogenicity samples collected, 125 useable interferon gamma (IFNg) samples, 116 usable interferon gamma (IFNg) sample pairs.","reportingStatus":"POSTED","paramType":"COUNT_OF_UNITS","unitOfMeasure":"lab samples","timeFrame":"Baseline to 1 year","typeUnitsAnalyzed":"lab samples","denomUnitsSelected":"lab samples","groups":[{"id":"OG000","title":"Zoster Vaccine Live (Zostavax)","description":"Zostavax (zoster vaccine live) is used to prevent herpes zoster virus (shingles) in people age 50 and older. Patients randomized to this arm will receive active Herpes Zoster Vaccine. It is administered as a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.\n\nHerpes Zoster Vaccine"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"254"}]},{"units":"lab samples","counts":[{"groupId":"OG000","value":"116"}]}],"classes":[{"categories":[{"title":"≤ Baseline","measurements":[{"groupId":"OG000","value":"87"}]},{"title":"Within 20%","measurements":[{"groupId":"OG000","value":"2"}]},{"title":"> 20%","measurements":[{"groupId":"OG000","value":"27"}]}]}]},{"type":"SECONDARY","title":"Number of Samples With Confirmed Varicella","description":"Evaluated all serious adverse events (SAEs) AND non-serious varicella zoster virus (VZV) events","populationDescription":"Lab samples collected for testing for varicella","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"lab sample","timeFrame":"\"Placebo Normal Saline Arm/Group was assessed up to 6 months and the \"Zoster Vaccine Live (Zostavax)\" Arm/Group was assessed up to 1 year","typeUnitsAnalyzed":"lab sample","denomUnitsSelected":"lab sample","groups":[{"id":"OG000","title":"Zoster Vaccine Live (Zostavax)","description":"Zostavax (zoster vaccine live) is used to prevent herpes zoster virus (shingles) in people age 50 and older. Patients randomized to this arm will receive active Herpes Zoster Vaccine. It is administered as a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.\n\nHerpes Zoster Vaccine"},{"id":"OG001","title":"Placebo Normal Saline","description":"Saline injection: patients randomized to this arm will receive a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.\n\nPlacebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"310"},{"groupId":"OG001","value":"307"}]},{"units":"lab sample","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}]}],"classes":[{"title":"Total Samples Tested","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}]}]},{"title":"Total Sample with Confirmed Varicella","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Vaccine Tolerability Within 42 Days Following Vaccination.","description":"Patient self report data in the form of a diary to include injection site reactions; symptoms of swelling, redness or tenderness. Diary was completed from study injection administration up to 6 week visit","populationDescription":"7 participants from the Zostavax arm and 8 participants from the placebo arm did not complete 6 week visit for various a reasons (e.g., lost to follow up, consent withdrawn , etc.)","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"42 days post vaccination","groups":[{"id":"OG000","title":"Zoster Vaccine Live (Zostavax)","description":"Zostavax (zoster vaccine live) is used to prevent herpes zoster virus (shingles) in people age 50 and older. Patients randomized to this arm will receive active Herpes Zoster Vaccine. It is administered as a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.\n\nHerpes Zoster Vaccine"},{"id":"OG001","title":"Placebo Normal Saline","description":"Saline injection: patients randomized to this arm will receive a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.\n\nPlacebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"303"},{"groupId":"OG001","value":"299"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"13"}]}]}]},{"type":"SECONDARY","title":"Evaluate Rheumatoid Arthritis Disease Activity Using the Clinical Disease Activity Index (CDAI)","description":"Rheumatoid arthritis disease activity will be measured using the clinical disease activity index (CDAI). Clinical disease activity index (CDAI) is a measure of rheumatoid arthritis disease activity and is scored on a scale ranging from 0-76, with lower numbers indicated better control of disease. Values \\<=10 are consistent with low disease activity or remission.","populationDescription":"120 participants on Zostavax arm and 129 participants on placebo arms were non-rheumatoid arthritis participants.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"42 days post vaccination","groups":[{"id":"OG000","title":"Zoster Vaccine Live (Zostavax)","description":"Zostavax (zoster vaccine live) is used to prevent herpes zoster virus (shingles) in people age 50 and older. Patients randomized to this arm will receive active Herpes Zoster Vaccine. It is administered as a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.\n\nHerpes Zoster Vaccine"},{"id":"OG001","title":"Placebo Normal Saline","description":"Saline injection: patients randomized to this arm will receive a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.\n\nPlacebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"190"},{"groupId":"OG001","value":"178"}]}],"classes":[{"title":"CDAI at Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"9.54","spread":"10.6"},{"groupId":"OG001","value":"9.34","spread":"9.77"}]}]},{"title":"CDAI at week 6","categories":[{"measurements":[{"groupId":"OG000","value":"10.48","spread":"10.93"},{"groupId":"OG001","value":"10.31","spread":"10.87"}]}]},{"title":"Changes in CDAI","categories":[{"measurements":[{"groupId":"OG000","value":"0.77","spread":"7.33"},{"groupId":"OG001","value":"0.98","spread":"8.55"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Adverse events and serious adverse events (SAEs) within 42 days of vaccination (placebo and vaccine). 6 months (final safety assessment for placebo arm).Serious Adverse Events (SAEs) up to 1 year (final safety assessment for treatment arm).","description":"Serious adverse events (SAEs) AND non-serious varicella zoster virus events. SAEs will include all that satisfy the FDA-accepted definition of SAEs (results in death, life threatening, results in or prolongs hospitalization, and any Herpes Zoster event). Adverse events (non-serious) include rashes,blisters,fever of greater than 101,sickness/illness. Also, any redness, swelling, tenderness of the injection site or any other body part.","eventGroups":[{"id":"EG000","title":"Zoster Vaccine Live (Zostavax)","description":"Zostavax (zoster vaccine live) is used to prevent herpes zoster virus (shingles) in people age 50 and older. Patients randomized to this arm will receive active Herpes Zoster Vaccine. It is administered as a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.\n\nHerpes Zoster Vaccine","deathsNumAffected":3,"deathsNumAtRisk":310,"seriousNumAffected":10,"seriousNumAtRisk":310,"otherNumAffected":120,"otherNumAtRisk":310},{"id":"EG001","title":"Placebo Normal Saline","description":"Saline injection: patients randomized to this arm will receive a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.\n\nPlacebo","deathsNumAffected":0,"deathsNumAtRisk":307,"seriousNumAffected":8,"seriousNumAtRisk":307,"otherNumAffected":75,"otherNumAtRisk":307}],"seriousEvents":[{"term":"Ductal carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":310},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":307}]},{"term":"Pseudoseizures","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":310},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":307}]},{"term":"Syncope and collapse","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Blocked Bowel","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":310},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":307}]},{"term":"Respiratory Syncytial Virus Pneumonia","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Sepsis due to pyelonephritis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":307}]},{"term":"Right groin pain secondary to edema of the right hip adductor","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":310},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":307}]},{"term":"Kidney stone","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":310},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":307}]},{"term":"Left Ureteral Obstruction","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":310},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":307}]},{"term":"Pyelonephritis","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Chest pain","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Elevated blood pressure","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Hip Fracture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":310},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":307}]},{"term":"Pneumonia","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Death","organSystem":"Congenital, familial and genetic disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":310},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":307}]}],"otherEvents":[{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":310},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":307}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Eye pain/Redness","organSystem":"Eye disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":310},{"groupId":"EG001","numEvents":14,"numAffected":11,"numAtRisk":307}]},{"term":"Injection Site Reaction","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":61,"numAffected":47,"numAtRisk":310},{"groupId":"EG001","numEvents":13,"numAffected":7,"numAtRisk":307}]},{"term":"Infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":8,"numAtRisk":310},{"groupId":"EG001","numEvents":18,"numAffected":9,"numAtRisk":307}]},{"term":"Anaphylaxis","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Back pain","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":310},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":307}]},{"term":"Blister","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":307}]},{"term":"Burn","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Bug Bites","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Joint Pain","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":310},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":307}]},{"term":"Fever, Flu like Symptom","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":310},{"groupId":"EG001","numEvents":12,"numAffected":8,"numAtRisk":307}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":310},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":307}]},{"term":"Psoriasis Flare","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":310},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":307}]},{"term":"Ankle Sprain","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Arthritis pain","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Chelitis","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":310},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":307}]},{"term":"Cold","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":310},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":307}]},{"term":"Dizziness","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Edema","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Foot and Groin Injury","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Headache , Migraine","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":310},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":307}]},{"term":"Sore Throat","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Fracture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":310},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":307}]},{"term":"Poison Ivy","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Ruptured vericose vein","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Sprained ankle","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Angiomyolipoma","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Cyst","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":310},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":307}]},{"term":"Cat Bite","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":310},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":307}]},{"term":"Heart Irregularities","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Herpes sore","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":310},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":307}]},{"term":"Hives","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Bursitis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Canker sore","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"hidradenitis","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Low Blood Sugar","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Lower Extremity Pain","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Law Pain","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":310},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":307}]},{"term":"Not Specifies","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":20,"numAtRisk":310},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":307}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Dr. Jeffrey R. Curtis","organization":"University of Alabama at Birmingham","email":"jrcurtis@uabmc.edu","phone":"205-975-2176"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2020-08-08","uploadDate":"2020-10-22T19:02","filename":"Prot_SAP_000.pdf","size":13873386}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D001172","term":"Arthritis, Rheumatoid"},{"id":"D001168","term":"Arthritis"},{"id":"D015535","term":"Arthritis, Psoriatic"},{"id":"D011565","term":"Psoriasis"},{"id":"D013167","term":"Spondylitis, Ankylosing"},{"id":"D003424","term":"Crohn Disease"}],"ancestors":[{"id":"D007592","term":"Joint Diseases"},{"id":"D009140","term":"Musculoskeletal Diseases"},{"id":"D012216","term":"Rheumatic Diseases"},{"id":"D003240","term":"Connective Tissue Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"},{"id":"D001327","term":"Autoimmune Diseases"},{"id":"D007154","term":"Immune System Diseases"},{"id":"D025242","term":"Spondylarthropathies"},{"id":"D025241","term":"Spondylarthritis"},{"id":"D013166","term":"Spondylitis"},{"id":"D013122","term":"Spinal Diseases"},{"id":"D001847","term":"Bone Diseases"},{"id":"D017444","term":"Skin Diseases, Papulosquamous"},{"id":"D012871","term":"Skin Diseases"},{"id":"D000089183","term":"Axial Spondyloarthritis"},{"id":"D000844","term":"Ankylosis"},{"id":"D015212","term":"Inflammatory Bowel Diseases"},{"id":"D005759","term":"Gastroenteritis"},{"id":"D005767","term":"Gastrointestinal Diseases"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D007410","term":"Intestinal Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D014612","term":"Vaccines"},{"id":"D053061","term":"Herpes Zoster Vaccine"},{"id":"D000077330","term":"Saline Solution"}],"ancestors":[{"id":"D001688","term":"Biological Products"},{"id":"D045424","term":"Complex Mixtures"},{"id":"D019433","term":"Chickenpox Vaccine"},{"id":"D022283","term":"Herpesvirus Vaccines"},{"id":"D014765","term":"Viral Vaccines"},{"id":"D000077324","term":"Crystalloid Solutions"},{"id":"D007552","term":"Isotonic Solutions"},{"id":"D012996","term":"Solutions"},{"id":"D004364","term":"Pharmaceutical Preparations"}]}},"hasResults":true}